Jospiten

Lercanidipine, the active ingredient in Jospiten, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients and works by relaxing vascular smooth muscle to lower blood pressure.

GNH USA supplies Jospiten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to manage conditions within the hypertension disease family.

Hypertension: reduces elevated blood pressure and helps achieve target blood pressure goals. Essential hypertension: provides long‑term control of primary high blood pressure. Isolated systolic hypertension: lowers systolic pressure in patients with age‑related vascular stiffness.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation with reddening of skin. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic injury: signs of liver dysfunction. - Severe allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with lercanidipine, certain safety considerations should be observed.

Monitor blood pressure: ensure adequate control and avoid excessive lowering. Assess hepatic function: use caution in patients with liver impairment. Caution in elderly: start with the lowest effective dose. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Consider drug interactions: review concomitant CYP3A4 inhibitors or inducers. Store at room temperature: keep in the original pack, protect from moisture.

Lercanidipine can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels. - Grapefruit juice: can increase drug exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower effectiveness.

Moderate Interactions (Monitor Closely):\n- Diuretics: additive hypotensive effect, monitor blood pressure. - Beta‑blockers: combined effect may cause excessive blood pressure reduction. - ACE inhibitors or ARBs: increased risk of symptomatic hypotension.